Join the Ozempic group to help and get support from people like you.
Ozempic News (Page 11)
Semaglutide Products Being Sold Online Without Prescriptions
FRIDAY, Aug. 2, 2024 – Semaglutide products are being sold online, with products likely unregistered or unlicensed, according to a research letter published online Aug. 2 in JAMA Network Open. Amir...
Legit Ozempic Sales Soar While Counterfeits Put Patients in Danger
FRIDAY, Aug. 2, 2024 – Two new studies show how eager Americans are to obtain either safe, legitimate versions of Ozempic or counterfeit and potentially dangerous forms of the diabetes/weight-loss...
Semaglutide Seems Beneficial for Comorbid T2DM, Tobacco Use Disorder
MONDAY, July 29, 2024 – For patients with type 2 diabetes mellitus (T2DM) and tobacco use disorder (TUD), new use of semaglutide is associated with lower risk of TUD-related health care measures...
FDA Warns of Accidental Overdoses from Compounded Versions of Ozempic
TUESDAY, July 30, 2024 – People taking compounded versions of Ozempic have been overdosing on the drug, the U.S. Food and Drug Administration warns. These ODs typically are due to miscommunications...
Ozempic's Latest Role: Helping Smokers Quit
TUESDAY, July 30, 2024 – Smokers with diabetes or obesity who take semaglutide (Ozempic/Wegovy) might reap an added benefit: Help in quitting smoking. A yearlong study found that, compared to people...
A Cardiologist Answers Your Questions on New Weight-Loss Meds, Ozempic and Zepbound
MONDAY, Feb. 12, 2024 – Weight loss drugs like Ozempic and Zepbound can lead to better heart health for people struggling with excess weight or diabetes, a University of Michigan cardiologist says....
A Cardiologist Answers Your Questions on New Weight-Loss Meds, Ozempic and Zepbound
MONDAY, Feb. 12, 2024 – Weight loss drugs like Ozempic and Zepbound can lead to better heart health for people struggling with excess weight or diabetes, a University of Michigan cardiologist says....
FDA Medwatch Alert: Drug Safety Communication: Certain Type of Medicines Approved for Type 2 Diabetes and Obesity - Update on FDA’s Ongoing Evaluation of Reports of Suicidal Thoughts or Actions
ISSUE: The FDA has been evaluating reports of suicidal thoughts or actions in patients treated with a class of medicines called glucagon-like peptide-1 receptor agonists (GLP-1 RAs; see the list in...
FDA Medwatch Alert: FDA Warns Consumers Not to Use Counterfeit Ozempic (semaglutide) Found in U.S. Drug Supply Chain
December 21, 2023 – FDA continues to investigate counterfeit Ozempic (semaglutide) injection 1 milligram (mg) in the legitimate U.S. drug supply chain and has seized thousands of units of the...
FDA Medwatch Alert: FDA Issues Warning About Compounded Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss
On May 30, 2023, the FDA posted information about medications containing semaglutide marketed for type 2 diabetes or weight loss. There are currently three FDA-approved semaglutide products which are...
Novo Nordisk Receives FDA Approval of Higher-Dose Ozempic 2 mg Providing Increased Glycemic Control for Adults with Type 2 Diabetes
Ozempic® demonstrated 2.1% blood sugar reduction and also weight loss in adults with type 2 diabetes with new 2 mg dose1 PLAINSBORO, N.J., March 28, 2022 /PRNewswire/ – Novo Nordisk today ...
FDA Approves Ozempic (semaglutide) for Cardiovascular Risk Reduction in Adults with Type 2 Diabetes and Known Heart Disease
PLAINSBORO, N.J., Jan. 16, 2020 /PRNewswire/ – Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Ozempic (semaglutide) injection 0.5 mg...
Novo Nordisk Receives FDA Approval of Ozempic (semaglutide) Injection For the Treatment of Adults with Type 2 Diabetes
December 5, 2017 – Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) approved its New Drug Application (NDA) for Ozempic (semaglutide) injection 0.5 mg or 1 mg, a...
Further information
Related condition support groups
Weight Loss (Obesity / Overweight), Chronic Kidney Disease, Cardiovascular Risk Reduction, Diabetes, Type 2